Previous studies confirmed that FAM83A-AS1 could promote the expression of intracellular FAM83A and thus confers tumor cells with EGFR-TKI resistance30-32, indicating that targeting FAM83A-AS1 might have the potential to reverse EGFR-TKI resistance in LUAD. The gene discussed is EGFR; the disease is neoplasm.